Emcure Pharma, Gennova Biopharma resolves all legal disputes with HDT Bio
Pune: Emcure Pharmaceuticals Ltd. and its biotech subsidiary, Gennova Biopharmaceuticals Ltd. have amicably resolved all legal disputes with HDT Bio Corp. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed.
Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines will once again collaborate on the development and commercialization of mRNA vaccines.
The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields.
“EMCURE is delighted that the misunderstanding between us and HDT not only stands resolved but we have widened the scope of our technical collaboration on a long term basis. mRNA platform will be the launching pad for our foray into vaccines for tuberculosis, rabies, dengue and other infectious diseases and our collaboration with HDT will be mutually beneficial,” observed Satish Mehta, CEO & Managing Director of EMCURE.
CEO of HDT, Dr Steve Reed, echoed Mehta’s sentiments and added that “HDT’s proprietary technology, combined with Emcure’s & Gennova’s innovation and manufacturing excellence and established distribution network will bring life-saving vaccines to countless people. We are committed to a successful relationship with Emcure and Gennova.”
Established in 1981, Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
Read also: Sanofi India, Emcure Pharma forge exclusive partnership for cardiovascular product distribution
